Research
Verastem Oncology’s portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways in cancer. These signaling pathways are abnormal in cancer and promote cancer cell survival and tumor growth.
Our programs target phosphoinositide 3-kinase (PI3K-delta/gamma), focal adhesion kinase (FAK), and RAF/MEK. These signaling pathways are abnormal in cancer and promote cancer cell survival and tumor growth. Preclinical research has shown that these targets also contribute to the protective nature of the tumor microenvironment, thereby limiting the effectiveness of anti-cancer treatments.